Last reviewed · How we verify
clofarabine (IV formulation)
Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to cell death in rapidly dividing cancer cells.
Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to cell death in rapidly dividing cancer cells. Used for Relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and adult patients, Relapsed or refractory acute myeloid leukemia (AML).
At a glance
| Generic name | clofarabine (IV formulation) |
|---|---|
| Also known as | Clolar®, Evoltra® |
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | Nucleoside analog |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Clofarabine works by incorporating into DNA and causing DNA strand breaks, which triggers apoptosis in cancer cells. This mechanism is particularly effective against leukemia cells, which have a high rate of cell division.
Approved indications
- Relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and adult patients
- Relapsed or refractory acute myeloid leukemia (AML)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Febrile neutropenia
Key clinical trials
- Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL) (PHASE2)
- Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients (PHASE2)
- A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) (PHASE3)
- Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia (PHASE2)
- Clofarabine in High Risk Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
- Clofarabine in Adult Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clofarabine (IV formulation) CI brief — competitive landscape report
- clofarabine (IV formulation) updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI